Tolvaptan: over-rapid increase in serum sodium and risk of serious neurological events
23rd April 2012
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has warned that treatment with tolvaptan (Samsca, Otsuka) can result in over-rapid correction of hyponatraemia, which can lead to serious neurological events. They give specific advice for healthcare professionals on monitoring of serum sodium and the acceptable rate of rise of serum sodium during treatment and highlight that co-administration of other drugs or fluids with a high sodium content (e.g. normal or hypertonic saline) is not recommended. They also warn that tolvaptan may reduce the effect of vasopressin analogues (e.g. desmopressin) used to control or prevent bleeding.
- CQC annual report: safer management of controlled drugs
- Sativex approved in Wales to treat MS symptoms on NHS
- Ketamine rescheduling consultation
- Levobupivacaine 250mg/200mL epidural infusion bags supply problem
- Dexamfetamine sulfate oral solution now authorized
- Cochrane review: Levetiracetam for neuropathic pain in adults
- Cochrane review: Topical lidocaine for neuropathic pain in adults
- PCF4+ 2013 e-book now half price!
- Class 2 Medicines Recall: Buccolam (midazolam) oromucosal solutions
- Cochrane review: Oxycodone for neuropathic pain and fibromyalgia in adults